Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults

Abstract

OBJECTIVES To assess adverse effects of pharmacologic antidepressants for treatment of major depressive disorder (MDD) in adults 65 years of age or older. DESIGN Systematic review and meta‐analysis. SETTING Specialist or generalist outpatient setting, rehabilitation facility, and nursing facilities. PARTICIPANTS Persons 65 years and older with MDD. INTERVENTION Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine, trazodone, vilazodone, or vortioxetine compared with another antidepressant, placebo, or nonpharmacologic therapy. MEASUREMENTS Adverse events, arrhythmias, cognitive impairment, falls, fractures, hospitalization, mortality, QTc prolongation, serious adverse events, and withdrawals due to adverse events. RESULTS Nineteen randomized controlled trials and two observational studies were included. Most studies evaluated treatment of the acute phase (<12 wk) of MDD of moderate severity. SSRIs led to a statistically similar frequency of overall adverse events vs placebo (moderate strength of evidence [SOE]), but SNRIs caused more overall adverse events vs placebo (high SOE) during the acute treatment phase. Both SSRIs and SNRIs led to more study withdrawals due to adverse events vs placebo (SSRIs low SOE; SNRIs moderate SOE). Duloxetine led to a more falls vs placebo (moderate SOE) during 24 weeks of acute and continuation treatment of MDD. CONCLUSION In patients 65 years of age or older with MDD, treatment of the acute phase of MDD with SNRIs, but not SSRIs, was associated with a statistically greater number of overall adverse events vs placebo. SSRIs and SNRIs led to a greater number of study withdrawals due to adverse events vs placebo. Duloxetine increased the risk of falls that as an outcome was underreported in the literature. Few studies examined head‐to‐head comparisons, most trials were not powered to evaluate adverse events, and results of observational studies may be confounded. Comparative long‐term studies reporting specific adverse events are needed to inform clinical decision making regarding choice of antidepressants in this population. J Am Geriatr Soc 67:1571–1581, 2019

Patterns of Symptom Management Medication Receipt at End-of-Life Among Medicare Beneficiaries With Lung Cancer

“…33 On the other hand, depression is amenable to medication therapy, yet fewer than 30% of patients in this study received antidepressants at EOL-1, which is low relative to symptom prevalence in this population. Clinicians may be reluctant to prescribe antidepressants to older adults because of risk of major adverse events such as falls or fractures, 34 intolerable side effects such as nausea and dizziness, or lack of time to receive benefit if prognosis is poor. 35 When we combine antidepressants and anxiolytics, we find that almost half of our study patients received medications for emotional distress.…”

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors

“…Both of these medications are indicated as first-line therapy for the treatment of depression. A few studies suggested that SSRIs are prescribed more often as the first medication used to treat depression [11,15]. It was not expected that there would be a significant difference in patient experience, and, thus, no difference in ratings was expected.…”

Transcranial Photobiomodulation with Near-Infrared Light from Childhood to Elderliness: Simulation of Dosimetry

“…MDD can develop at any age, and is considered the leading cause of disability in the US for individuals between the ages of 15 and 44. [2][3][4] The two most commonly used treatments for MDD are antidepressants (87.0%) and psychotherapy (23.2%). 5 Several known challenges have been faced by these treatment approaches: 1) frequent relapses of the cognitive therapy 6 and 2) burdensome side-effects of antidepressant medication.…”

“…15 A wide range of studies, in both animal models and humans, have shown that PBM causes minimal or no adverse effects while producing therapeutic effects. 10,16,17 Although MDD has a broad age of onset, 2,4 most previously published studies have focused on t-PBM treatments in only middle-aged adult brain models. 18 However, personalization of treatments is key to increasing success rate and tolerability; therefore our interest is in developing precise PBM treatment strategies adapted for individual patients.…”